Elastrin Therapeutics Inc.

Elastrin Therapeutics develops drug loaded nanoparticles targeting damaged elastin for the effective treatment of life-threatening diseases - Restoring the elastic of life

Chief Executive Officer

Eagles4Life

CEO & Founder

True Nature Retreat Center

Catalyzing personal growth through retreats, founded in clinical research & worldwide education

Co-Founder & CFO

SLS Partnering GmbH

International Investor Partnering conference for the Diagnostics, Digital Health and Research Tool industry

DxPx Organizer

SilverSky LifeSciences

Corporate finance and non-dilutive funding at national and international level for startup and MedTech companies

Business builder taking up senior executive roles in portfolio companies.

Principal Consultant & Fund Raising Expert

Grünenthal Group

Co-designed and implemented a new Operating Model of the R&D area as Implementation PMO Lead. Supported the CSO to shape overall R&D strategy and leads selected projects. Acted as the point of contact between senior management and employees in R&D.

Chief of Staff / Planning Director for CSO area

Designed and implemented a Performance Management program (KPIs, Tiers). Acted as a coach for different layers to continuously improve their performance.	Analyzed past 10 years of R&D Productivity (Cycle Times, PoS and Costs).

Drug Development Performance and Improvement Lead

Redesigned development process with timeline reduction of 7 months with ROI of 16 m€ at peak sales. Secured productivity increase in Global Drug Safety Data Operations of 10%. Redefined Business Model for 100-FTE CMC unit leading to 90 k€ yearly savings.

GI Business Transformation In-house Consultant

Identify & drive impactful operational excellence initiatives within a department or business area or across departments or business areas engaging all stakeholders. Introduce a solid performance management system in line with the annual objectives. Enthuse and help build capabilities of all layers  to continuously improve its processes, performance and mindsets.

Operational Excellence In-house Consultant

Provide oversight on the global Pharmacovigilance system including infrastructure, key processes, compliance metrics, safety profiles and safety risks of all medicinal products to the QPPV.  Finalized ~ 50 new Pharmacovigilance Agreements with partners. Mitigated regulatory compliance issues involving senior Risk Management Leaders.

Senior Manager QPPV & Alliance Office

Identification and support of implementation of pharmacovigilance regulatory requirements (guidelines, regulations, directives, reporting obligations, etc.).
Interaction with competent authorities, external organizations, internal departments and Grünenthal subsidiaries worldwide in collaboration with the Qualified Person for Pharmacovigilance (QPPV).
Support of the QPPV in having oversight over the global PV system. This includes the monitoring of global quality metrics concerning drug safety and regular reports from subsidiaries.
Preparation, negotiation, oversight and maintenance of global drug safety agreements.
Support of globalization of standard operating procedures (SOPs) and implementation in the respective Grünenthal subsidiaries in collaboration with Quality Assurance (QA).
Organization and support of global drug safety training.
Preparation and leading of documentation for audits and inspections together with the Corporate Quality Assurance Department.
Management of contributions from external experts and specialists from other Grünenthal departments in order to achieve the corporate goals in the drug safety environment, in collaboration with the QPPV.

Manager QPPV & Alliance office

University of Antwerp

Cysteine protease inhibitors for protozoan infections: metacaspases as promising new targets.

Metacaspasen (MCAs) are a new family of cystein proteases found in parasitic protozoa and whom form a valuable new drug target in drug research and development. These proteases are possibly involved in cell death, considered vital for the survival of the parasite and are fundamentally different from the orthologous humane caspases. The objective of this doctorates thesis is the development of powerful and selective inhibitors of the MCA2 of Trypanosoma brucei, with high activity in vitro and low cytotoxicity.

PhD researcher

Life science entrepreneur with a passion for bringing new innovation to patients in need. As a leader, I love balancing the creative mind with the need to produce results. 

Currently CEO of Elastrin Therapeutics where we develop groundbreaking new technology capable of reversing tissue and organ calcification.

Taplio

Matthias Breugelmans's Linkedin Analytics

Want to drive more opportunities from LinkedIn?

Taplio

.css-1jgreyo{background-image:linear-gradient(284deg, rgba(39,43,72,1) 0%, rgba(33,47,183,1) 100%);color:transparent;-webkit-background-clip:text;background-clip:text;}Matthias Breugelmans's Linkedin Analytics

Want to drive more opportunities from LinkedIn?

Matthias Breugelmans's Linkedin Analytics